The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 102.50
Bid: 101.00
Ask: 104.00
Change: 4.50 (4.59%)
Spread: 3.00 (2.97%)
Open: 97.00
High: 102.50
Low: 97.00
Prev. Close: 98.00
DXRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Expanded lab network and data capabilities

27 Feb 2024 07:00

RNS Number : 5258E
Diaceutics PLC
27 February 2024
 

Diaceutics grows its lab network and data capabilities in Europe

 

New data will deliver enhanced insights to Diaceutics' customers and drive new sales opportunities across multiple geographies

 

Belfast and London, 27 February 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce it has expanded its data supply network which will significantly increase the number of labs through which Diaceutics is sourcing data in Europe and will broaden the Company's European data coverage. This data will accelerate the rollout of the DxRx Signal product in key EU markets of Germany, France, Italy, Spain and the United Kingdom (DxRx Signal has only previously been offered by Diaceutics in the US market).

The increased data is now available to Diaceutics customers enabling them to find more patients eligible for their new and innovative therapies.

Jordan Clark, Chief Data Officer of Diaceutics commented: "This data will further endorse our position as a leading provider of data to biotech and pharma companies as they commercialize their products, find and deliver therapies to patients across multiple geographies."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer. 

 

Enquiries: 

Diaceutics PLC?

 Tel: +44 (0)28 9040 6500 

Ryan Keeling, Chief Executive Officer 

Nick Roberts, Chief Financial Officer

Jordan Clark, Chief Data Officer

investorrelations@diaceutics.com 

Stifel Nicolaus Europe Limited (Nomad & Broker) 

Tel: +44 (0)20 7710 7600 

Ben Maddison 

Nick Harland 

Kate Hanshaw 

Alma Strategic Communications 

Tel: +44 (0)20 3405 0205 

Caroline Forde 

diaceutics@almastrategic.com 

Kinvara Verdon 

 

About Diaceutics 

At Diaceutics we believe that?every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDXGDDDBDDGSL
Date   Source Headline
9th Dec 20217:00 amRNSTest Signal Launch and Contract Wins
1st Dec 20215:22 pmRNSPDMR Shareholding/Share Incentive Plan
9th Nov 20214:57 pmRNSPDMR Shareholding/Share Incentive Plan
1st Oct 20211:19 pmRNSPDMR Shareholding/Share Incentive Plan
1st Oct 202112:32 pmRNSHolding(s) in Company
28th Sep 20217:00 amRNSPurchase/Transfer of Shares and PDMR Shareholdings
21st Sep 20217:00 amRNSNominated as finalists for Health Tech Awards 2021
14th Sep 20217:00 amRNSHalf-year Report
13th Sep 20217:00 amRNSDXRX Platform Contract Win
8th Sep 20217:00 amRNSTwo new experts join the Diaceutics Advisory Panel
1st Sep 20217:00 amRNSPDMR Shareholding/Share Incentive Plan
31st Aug 20217:00 amRNSNotice of Investor Presentation
30th Jul 20214:54 pmRNSPDMR Shareholding/Share Incentive Plan
8th Jul 20217:00 amRNSTrading Update
1st Jul 20217:00 amRNSIssue of Share Options and PDMR Shareholdings
29th Jun 20214:56 pmRNSPDMR Shareholding/Share Incentive Plan
24th Jun 20217:00 amRNSNew Contract Wins
18th Jun 20217:00 amRNSPurchase of Shares and PDMR Shareholding
16th Jun 20217:00 amRNSCapital Markets Day and KPI Update
7th Jun 20216:23 pmRNSPDMR Shareholding/Share Incentive Plan
7th Jun 20217:00 amRNSNotice of Capital Markets Day
4th Jun 20217:00 amRNSPresenting data on COVID impact on cancer at ASCO
21st May 20211:49 pmRNSHolding(s) in Company
21st May 20217:00 amRNSChange of Adviser
19th May 20213:24 pmRNSResult of AGM
13th May 20217:00 amRNSLGC SeraCare Partnership
12th May 20215:58 pmRNSSale of Shares and PDMR Shareholding
5th May 20216:03 pmRNSHolding(s) in Company
4th May 20213:11 pmRNSSale of Shares and Director/PDMR Shareholding
30th Apr 202111:01 amRNSShare Incentive Plan
21st Apr 20217:00 amRNSNotice of AGM and posting of Annual Report
12th Apr 20217:00 amRNSNew Vice President of Operations in Asia
8th Apr 20219:49 amRNSTransfer of Shares and Director/PDMR Shareholding
7th Apr 20217:58 amRNSTransfer of Shares and Director/PDMR Shareholding
6th Apr 202111:12 amRNSIssue of Share Options/PDMR Shareholdings
1st Apr 20217:00 amRNSCOVID-19 Testing Data licensing agreement
30th Mar 20217:00 amRNSNew lease agreement and related party transaction
15th Mar 20217:00 amRNSFinal Results
8th Mar 20217:00 amRNSNotice of Results
4th Mar 202112:49 pmRNSNew Vice President of Finance appointment
21st Jan 20217:00 amRNSQuarterly media update
11th Jan 20219:56 amRNSHolding(s) in Company
11th Jan 20217:00 amRNSTrading update
22nd Dec 20207:01 amRNSDirectorate Change
22nd Dec 20207:00 amRNSDirectorate Change
10th Dec 20203:10 pmRNSHolding(s) in Company
17th Nov 20207:00 amRNSEuropean international award win
10th Nov 20204:32 pmRNSHolding(s) in Company
28th Oct 20207:00 amRNSCommercial launch of DXRX
7th Sep 20202:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.